GlassScriptPhysician profile
Skye D Altieri
NPI 1821635475
$1,407.45
in general payments reported to CMS, 2019-2025
20 companies · $466 in 2025
The $466 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $99.85 · 2022: $127 · 2023: $396 · 2024: $319 · 2025: $466.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,180.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $328.44 | 2022-2025 | Stelara, Simponi, Simponi Aria |
| Gilead Sciences, INC. | $180.54 | 2021-2025 | Epclusa |
| Qol Medical, LLC | $168.15 | 2023-2025 | Sucraid, Sucraid |
| Phathom Pharmaceuticals, INC. | $88.36 | 2025 | Voquezna |
| Celltrion USA INC. | $82.21 | 2024-2025 | Vegzelma |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $61.32 | 2022-2024 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $55.70 | 2021-2025 | Gattex, Entyvio |
| Celgene Corporation | $54.53 | 2023-2024 | Zeposia |
| Aimmune Therapeutics, INC. | $53.50 | 2024-2025 | Zenpep |
| Regeneron Healthcare Solutions, INC. | $51.24 | 2022-2023 | Dupixent |
| Ardelyx, INC. | $43.86 | 2024 | Ibsrela |
| Madrigal Pharmaceuticals | $40.82 | 2025 | Rezdiffra |
| Corcept Therapeutics | $35.96 | 2023 | Korlym |
| Abbvie INC. | $34.74 | 2022-2024 | |
| Lilly USA, LLC | $32.56 | 2023 | Mounjaro |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $27.49 | 2022-2023 | |
| Evoke Pharma, INC. | $19.44 | 2024 | |
| Novo Nordisk INC | $18.68 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $15.89 | 2024 | Iqirvo |
| Pfizer INC. | $14.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Skye Altieri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.